IM156 for Malignant Neoplasm of Pancreas

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
MD Anderson Cancer Center, Houston, TX
Malignant Neoplasm of Pancreas+1 More
IM156 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

To learn if adding a new medication, IM156, to treatment with gemcitabine and nab-paclitaxel is safe and tolerable. The ability of this combination to improve the success of this treatment for these patients will also be studied.

Eligible Conditions

  • Malignant Neoplasm of Pancreas

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Malignant Neoplasm of Pancreas

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion and or average of 1 year

Year 1
National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0

Trial Safety

Safety Progress

1 of 3

Other trials for Malignant Neoplasm of Pancreas

Trial Design

2 Treatment Groups

Part 1 (IM156)
1 of 2
Part 2 (IM156)
1 of 2
Experimental Treatment

25 Total Participants · 2 Treatment Groups

Primary Treatment: IM156 · No Placebo Group · Phase 1

Part 1 (IM156)
Drug
Experimental Group · 1 Intervention: IM156 · Intervention Types: Drug
Part 2 (IM156)Experimental Group · 3 Interventions: IM156, Gemcitabine, Nab paclitaxel · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IM156
2017
Completed Phase 1
~30
Gemcitabine
2017
Completed Phase 3
~2940

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion and or average of 1 year
Closest Location: MD Anderson Cancer Center · Houston, TX
Photo of MD Anderson Cancer Center 1Photo of MD Anderson Cancer Center 2Photo of MD Anderson Cancer Center 3
2004First Recorded Clinical Trial
26 TrialsResearching Malignant Neoplasm of Pancreas
521 CompletedClinical Trials

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
12,930 Previous Clinical Trials
41,294,435 Total Patients Enrolled
225 Trials studying Malignant Neoplasm of Pancreas
72,066 Patients Enrolled for Malignant Neoplasm of Pancreas
M.D. Anderson Cancer CenterLead Sponsor
2,772 Previous Clinical Trials
1,795,187 Total Patients Enrolled
39 Trials studying Malignant Neoplasm of Pancreas
41,127 Patients Enrolled for Malignant Neoplasm of Pancreas
Shubham Pant, MDPrincipal InvestigatorM.D. Anderson Cancer Center
3 Previous Clinical Trials
174 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have measurable disease per RECIST 1.1 criteria [13], defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.
You are able to understand the nature and purpose of the study and the risks and benefits of participating in the study.
You have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma.
Patients must have received prior adjuvant therapy for pancreatic adenocarcinoma.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.